article information

Journal of Kermanshah University of Medical Sciences: Vol.18, issue 2; e74164
published online: May 29, 2014
article type: Research Article
received: October 05, 2013
accepted: March 11, 2014
DOI: https://doi.org/10.22110/jkums.v18i2.1552
Crossmark

Effects of Raloxifene and GnRH-a on VEGF expression in cultured human uterine leiomyoma cells

authors:

avatar Taravat Fakheri 1 , avatar Kamran Mansouri 2 , avatar Sahar Rashidi 1 , * , avatar Mansour Rezaei 3 , avatar Sara Daeichin 1 , avatar Anisodowleh Nankali 1

Maternity Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
Social Development and Health Promotion Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

how to cite: Fakheri T, Mansouri K, Rashidi S, Rezaei M, Daeichin S, et al. Effects of Raloxifene and GnRH-a on VEGF expression in cultured human uterine leiomyoma cells. J Kermanshah Univ Med Sci. 2014;18(2):e74164. https://doi.org/10.22110/jkums.v18i2.1552.

Abstract

Background: uterine leiomyoma is the most common benign pelvic tumor in women of reproductive age and is frequently associated with abnormal uterine bleeding and pelvic pressure. Combined therapy of gonadotropin-releasing hormone analogue (GnRH-a) and selective estrogen receptor inhibitors (raloxifene) reduce the  size of leiomyoma.
Methods: Twelve uterine leiomyomas were obtained from pre-menopausal women with regular menstrual cycles in the proliferative phase who underwent abdominal hysterectomy or myomectomy in Imam Reza Hospital. The patients had received no hormonal therapy for at least 6 months before surgery.The comparative effects of treatment with graded concentrations of raloxifene (in five groups with various concentrations of 1, 2, 4, 6 and 8 micrograms per milliliter, respectively) and GnRH-a (in five groups, with concentrations of 50, 100, 200, 300 and 400 micrograms per milliliter, respectively) and combination of these two on Vascular Endothelial Growth Factor (VEGF) and inhibition of leiomyoma cell proliferation were determined.
Results: in the three treatment groups with graded concentration of raloxifene and GnRH-a and combined therapy, VEGF content significantly decreased (P<0.05). The VEGF decreasing levels in the combined therapy, raloxifene and GnRH-a groups were 79.16%, 64.74% and 55.29%, respectively (p<0.05). The inhibition of cell growth was significantly different between the two treatment groups (P<0.05). The inhibition of cell growth in the combined therapy group was 70.77% followed by raloxifene (60.76%) and GnRH-a (15.83%), which indicated a significant difference (P<0.05). 
Conclusion: Treatment with graded concentrations of Raloxifene, GnRH-a and combination of both Raloxifene and GnRH-a significantly decreased the VEGF content and proliferation of leiomyoma cells.

Fulltext

 

 

References

  • 1.

    The references of this article is available on PDF.